Myosin Va Inhibitors
Myosin Va inhibitors constitute a diverse group of compounds that exert their effects on Myosin Va either directly or indirectly by targeting specific cellular processes involved in its motor activity. Blebbistatin, a myosin II ATPase inhibitor, impacts Myosin Va indirectly by disrupting the actin-myosin interaction crucial for its motor activity. This disruption prevents the conformational changes in Myosin Va necessary for binding to actin filaments, leading to the inhibition of Myosin Va-mediated processes. CK-666, CK-548, CK-636, CK-869, and CK-666 hydrochloride are Arp2/3 complex inhibitors that influence Myosin Va indirectly by disrupting actin dynamics. These compounds inhibit the Arp2/3 complex, leading to changes in actin polymerization that impact the association of Myosin Va with actin filaments. Latrunculin A, an actin polymerization inhibitor, also indirectly affects Myosin Va by disrupting actin dynamics.
Jasplakinolide, an actin polymerization promoter, indirectly influences Myosin Va by stabilizing actin filaments, resulting in increased actin density and altered cytoskeletal organization. ML-7 and ML-9, inhibitors of myosin light chain kinase (MLCK), modulate Myosin Va indirectly by preventing the phosphorylation of myosin light chains. This modulation impacts the activity and binding of Myosin Va to actin filaments. NSC23766, a Rac1 inhibitor, indirectly affects Myosin Va by inhibiting the activity of Rac1, a small GTPase involved in actin cytoskeleton regulation. By modulating Rac1, NSC23766 influences actin dynamics, thereby impacting the interaction of Myosin Va with actin filaments. Y-27632, a Rho-associated protein kinase (ROCK) inhibitor, indirectly influences Myosin Va by modulating actin filament organization through the inhibition of ROCK. In summary, Myosin Va inhibitors offer a diverse toolkit for precise modulation of its motor activity by directly targeting its ATPase function or indirectly influencing actin dynamics and cytoskeletal organization crucial for its function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Myosin II ATPase inhibitor, impacting Myosin Va indirectly by disrupting the actin-myosin interaction crucial for its motor activity. Blebbistatin prevents the conformational changes in myosin necessary for its binding to actin filaments, leading to inhibition of Myosin Va-mediated processes. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
Arp2/3 complex inhibitor affecting Myosin Va indirectly by disrupting actin dynamics. CK-666 inhibits the Arp2/3 complex, leading to alterations in actin polymerization that subsequently impact the association of Myosin Va with actin filaments. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Actin polymerization promoter impacting Myosin Va indirectly. Jasplakinolide stabilizes actin filaments, leading to increased actin density and altered cytoskeletal organization, which can influence the activity and binding of Myosin Va. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Actin polymerization inhibitor indirectly affecting Myosin Va. Latrunculin A binds to actin monomers, preventing their polymerization into filaments. This disruption of actin dynamics influences the association and activity of Myosin Va on actin filaments. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Myosin light chain kinase (MLCK) inhibitor impacting Myosin Va indirectly. ML-7 inhibits MLCK, a kinase responsible for phosphorylating myosin light chains. By preventing this phosphorylation, ML-7 modulates the activity of Myosin Va, altering its interaction with actin filaments. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Rho-associated protein kinase (ROCK) inhibitor indirectly affecting Myosin Va. Y-27632 inhibits ROCK, a kinase that regulates actin cytoskeleton dynamics. By inhibiting ROCK, Y-27632 modulates actin filament organization, influencing the interaction of Myosin Va with actin. | ||||||
CK-869 | 388592-44-7 | sc-507274 | 5 mg | $163.00 | ||
Arp2/3 complex inhibitor impacting Myosin Va indirectly through modulation of actin dynamics. CK-869 inhibits the Arp2/3 complex, leading to changes in actin polymerization that affect the association of Myosin Va with actin filaments. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
Myosin light chain kinase (MLCK) inhibitor influencing Myosin Va indirectly. ML-9 inhibits MLCK, preventing the phosphorylation of myosin light chains. This modulation of myosin light chain phosphorylation impacts the activity and binding of Myosin Va to actin filaments. | ||||||